Labopharm, Paladin deal
Labopharm granted Paladin exclusive rights to market pain compounds Intellitab-based twice-daily oxycodone-acetaminophen in Canada and in certain sub-Saharan African countries and twice-daily tramadol-acetaminophen in certain sub-Saharan African countries. The companies will collaborate on a development plan for the oxycodone-acetaminophen product, which recently completed a pharmacokinetic study, and share development costs in Canada, while Paladin is responsible for all development and regulatory costs in sub-Saharan Africa. Paladin has a right of first opportunity on a second Intellitab-based pain product in Canada. Labopharm's twice-daily tramadol-acetaminophen combination tablet is formulated using the company's Contramid controlled-release technology and is expected to be launched in Europe by year end 2011. Intellitab is an abuse-deterrent technology. ...